AI-based solution for brain age evaluation and Alzheimer's disease prediction

Lead Participant: INFERVISION UK LTD

Abstract

Dementia is the leading cause of death in the UK. Around 850,000 individuals are living with dementia, but only around 540,000 of these have received a diagnosis. An accurate early, or timely diagnosis of dementia can have many benefits including opening the door to future care and treatment. Dementia is a profoundly life-changing condition and reactions to a diagnosis can range from dismay and deep sadness to anger and despair. Early diagnosis allows people with dementia to receive appropriate treatment that can potentially help them maintain their cognitive function and quality of life for longer.

The proprietory AI solution developed by Infervision offers accurate and early stage dementia diagnosis and characterisation, and predicts the pre-symptomatic risk of developing dementia with high accuracy using MRI scans. Infervision's solution represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal imaging and non-imaging MRI data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics. The cutting-edge technology can analyse scans automatically and intelligently to deliver sensitive and precise micro-structural information about important tissue and organ structures, which can then be compared to data from healthy populations to identify the signs of dementia.

It is believed that this Infervision's AI solution has the potential to accelerate clinical pathways, standardise quality of care, improve patient outcomes, and save time during assessments for Dementia, as well as contribute to the development of disease-modifying therapies. The solution is intended to become a routine part of clinical practice and drug development because it provides clinicians, researchers, and imaging centres with reliable, quantitative, and objective diagnostic and prognostic data using the results of our intelligent analysis.

Lead Participant

Project Cost

Grant Offer

 

Participant

INFERVISION UK LTD

Publications

10 25 50